Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Concurrent Medication:~Allowed:~* Other medically indicated vaccinations, provided they are administered at least 2 weeks before or after any study injection.~* Alcohol use limited to 1 oz per day of 100 proof.~Patients must have:~* HIV infection without evidence of AIDS.~* CD4 count \> 500 cells/mm3.~Exclusion Criteria~Co-existing Condition:~Patients with the following symptoms or conditions are excluded:~* Current evidence of underlying lung or liver disease.~* Suspected or diagnosed allergy to any vaccine component.~* Medical contraindication to protocol participation.~* Undergoing allergy skin testing or desensitization.~Concurrent Medication:~Excluded:~* Antiretroviral therapy (unless clinically indicated and with approval of investigator).~* Immunosuppressive or immunomodulatory therapy.~* Nonsteroidal anti-inflammatory agents (except short-term therapy for acute conditions).~* Drugs with known hepatotoxicity.~* Alcohol intake \> 1 oz per day of 100 proof.~Patients with the following prior conditions are excluded:~* History of underlying lung disease.~* Abnormal chest radiograph within 2 weeks prior to first vaccine injection.~* History of underlying liver disease.~* Abnormal hepatitis B surface antigen or hepatitis C antibody test within 2 weeks prior to first vaccine injection.~* Abnormal liver function tests within 30 days prior to study entry.~* Evidence of uveitis by slit lamp exam within 2 weeks prior to study entry.~* Anergic as evidenced by negative skin test responses to all three antigens in a panel consisting of tetanus toxoid, mumps, and Candida albicans, within 6 weeks prior to first vaccine injection.~* Prior participation on an HIV vaccine trial.~Prior Medication:~Excluded within the past 3 months:~* Antiretroviral therapy.~* Immunosuppressive drugs.~* Alpha interferon or any immunomodulatory drugs.~* Any investigational HIV drugs or therapies. Current alcohol abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).